Iterum Therapeutics announced it has been granted a U.S. patent, number 12,544,337, covering a bilayer tablet comprising sulopenem etzadroxil and probenecid, methods for making the tablet, and methods for treating diseases such as uncomplicated urinary tract infection. The patent is projected to expire in December 2039, assuming all maintenance fees are paid and no term extensions are applied. This patent is eligible for listing in the FDA's Orange Book and would bring the total number of Iterum's U.S. patents listed there to five.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iterum Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9654248-en) on February 13, 2026, and is solely responsible for the information contained therein.